Kieran O'kane Biography and Net Worth

Chief Commercial Officer of Biodesix

Kieran O’Kane serves as the Chief Commercial Officer of Biodesix since March 2020. Kieran is an experienced commercial leader with deep expertise in oncology. With an academic background in Pharmacology, Kieran has over 25 years in the industry including over 10 product launches globally across pharma, medical device, and clinical diagnostics. Kieran has strong personal motivation to positively impact health outcomes which drives the engine of commercial growth at Biodesix.

Prior to joining Biodesix, Kieran led the Global Diagnostics Marketing team at Nanostring Technologies, a biotechnology company focused on developing cancer diagnostic tools. Kieran held various commercial leadership positions in sales and marketing functions, in addition to managing pricing, reimbursement, health technology appraisal and national payor strategy at companies including Biotheranostics, Cell Therapeutics, Eisai, Cephalon, Bristol-Myers Squibb, and Roche.

What is Kieran O'kane's net worth?: The estimated net worth of Kieran O'kane is at least $236.54 thousand as of February 23rd, 2026. Mr. O'kane owns 9,819 shares of Biodesix stock worth more than $236,540 as of July 1st. This net worth approximation does not reflect any other investments that Mr. O'kane may own. Learn More about Kieran O'kane's net worth.
How do I contact Kieran O'kane?: The corporate mailing address for Mr. O'kane and other Biodesix executives is , , . Biodesix can also be reached via phone at 303-417-0500 and via email at [email protected]. Learn More on Kieran O'kane's contact information.
Has Kieran O'kane been buying or selling shares of Biodesix?: Kieran O'kane has not been actively trading shares of Biodesix in the last ninety days. Most recently, Kieran O'kane sold 535 shares of the business's stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $12.78, for a transaction totalling $6,837.30. Following the completion of the sale, the insider now directly owns 9,819 shares of the company's stock, valued at $125,486.82. Learn More on Kieran O'kane's trading history.
Who are Biodesix's active insiders?: Biodesix's insider roster includes Robin Cowie (CFO), Scott Hutton (CEO), Kieran O'kane (Chief Commercial Officer), John Patience (Chairman), Gary Pestano (Chief Scientific Officer), Jack Schuler (Director), and Charles Watts (Director). Learn More on Biodesix's active insiders.
Are insiders buying or selling shares of Biodesix?: During the last twelve months, Biodesix insiders bought shares 7 times. They purchased a total of 517,301 shares worth more than $4,695,978.20. During the last twelve months, insiders at the sold shares 25 times. They sold a total of 11,592 shares worth more than $120,842.31. The most recent insider tranaction occured on February, 23rd when insider Gary Anthony Pestano sold 556 shares worth more than $7,105.68. Insiders at Biodesix own 23.2% of the company. Learn More about insider trades at Biodesix.
Information on this page was last updated on 2/23/2026.

Kieran O'kane Insider Trading History at Biodesix

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/23/2026	Sell	535	$12.78	$6,837.30	9,819
2/10/2026	Sell	584	$10.08	$5,886.72	8,885
1/16/2026	Sell	298	$8.15	$2,428.70	7,869
11/10/2025	Sell	25	$7.62	$190.50	7,362
8/13/2025	Sell	23	$8.40	$193.20	7,003
5/9/2023	Sell	61	$31.40	$1,915.40	1,861
11/9/2022	Sell	47	$20.80	$977.60	796
5/10/2022	Sell	79	$36.60	$2,891.40	381

Kieran O'kane Buying and Selling Activity at Biodesix

Biodesix Company Overview

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

Today's Range

Now: $24.22

$21.88

$24.71

50 Day Range

MA: $15.27

$9.84

$23.81

2 Week Range

Now: $24.22

$5.26

$24.71

Volume

93,272 shs

Average Volume

759,472 shs

Market Capitalization

$250.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.59